Abstract Context Each year the European Association of Urology (EAU) produce a document
based on the most recent evidence on the diagnosis, therapy, and follow-up of testicular …

Testicular cancer is a curable cancer. The success of physicians in curing the disease is
underpinned by multidisciplinary advances. Cisplatin-based combination chemotherapy and …

Germ-cell tumours (GCTs) affect predominantly younger males aged between 15 and 40
years, with nearly 74 500 new cases estimated globally in 2020. 1 About one-third of all GCT …

Testicular germ cell tumor (GCT) is the most common solid tumor in adolescent and young
adult men. Progress in the management of GCT has been made in the last 50 years, with a …

Abstract Background MiR-371~ 373 and miR-302/367 cluster over-expression occurs in all
malignant germ cell tumours (GCTs), regardless of age (paediatric/adult), site …

Background Testicular cancer is the most common solid tumour among young men in the
reproductive phase. After completing cancer treatment, up to 77% of cancer survivors report …

Testicular cancer is the first solid tumor with a remarkably high cure rate. This success was
only made possible through collaborative efforts of basic and clinical research. Most patients …

Germ cell tumours (GCTs) are a heterogeneous group of rare neoplasms that present in
different anatomical sites and across a wide spectrum of patient ages from birth through to …

PURPOSE Testicular cancer (TC) treatment is clearly associated with cardiovascular
morbidity and mortality. To enable development of preventive strategies for cardiovascular …

PURPOSE Cisplatin is the main systemic treatment modality for male type II germ cell tumors
(GCTs). Although generally very effective, 5%-10% of patients suffer from cisplatin-resistant …